ABEO
Abeona Therapeutics Inc.
$5.90
+2.25%
2026-05-08
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Key Fundamentals
P/E Ratio
5.74
Forward P/E
24.17
EPS (TTM)
$1.01
ROE
70.0%
Profit Margin
1223.1%
Debt/Equity
15.68
Price/Book
2.00
Beta
1.34
Market Cap
$329.9M
Avg Volume (10D)
1.1M
Recent Breakout Signals
No recent breakout signals detected for ABEO.
Recent Price Range (60 Days)
60D High
$6.07
60D Low
$4.23
Avg Volume
1.2M
Latest Close
$5.90
Get breakout alerts for ABEO
Sign up for Breakout Scanner to receive daily notifications when ABEO triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Abeona Therapeutics Inc. (ABEO) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ABEO daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ABEO operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.